[
    [
        {
            "time": "2018-01-03",
            "original_text": "Biogen's Multiple Sclerosis Drug Franchise Takes Another Hit",
            "features": {
                "keywords": [
                    "Biogen",
                    "Multiple Sclerosis",
                    "Drug Franchise",
                    "Hit"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "What’s Expected for Novo Nordisk’s Net Income Margin in 2018",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Net Income Margin",
                    "Expected"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "7 Europe Dividend ETFs for Overseas Income",
            "features": {
                "keywords": [
                    "Europe",
                    "Dividend ETFs",
                    "Overseas Income"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Novo Nordisk Expected to Report Flat Revenue in 2018",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Flat Revenue",
                    "Expected"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Analysts’ Recommendations for Novo Nordisk and Peers in 2018",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "Novo Nordisk",
                    "Peers"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Johnson & Johnson’s Oncology Segment’s Performance in 2017",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Oncology Segment",
                    "Performance",
                    "2017"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "The Swiss Stock Market Climbed Back Above 9,000 Points",
            "features": {
                "keywords": [
                    "Swiss Stock Market",
                    "Climbed",
                    "9,000 Points"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]